Skip to main content

Table 1 Characteristics of patients with or without surgical axillary staging

From: Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?

Characteristic

Whole cohort [cases (%)]

Matched cohort [cases (%)]

Non-staging group

Staging group

P

Non-staging group

Staging group

P

Total

6474

160,141

 

5561

5561

 

Diagnosis year

  

< 0.001

  

0.871

 2000–2003

2779 (42.9)

47,508 (29.7)

 

2362 (42.5)

2364 (42.5)

 

 2004–2008

2054 (31.7)

61,515 (38.4)

1759 (31.6)

1737 (31.2)

 2009–2012

1641 (25.3)

51,118 (31.9)

1440 (25.9)

1460 (26.3)

Race

  

< 0.001

  

0.423

 NHW

5130 (79.2)

124,187 (77.5)

 

4669 (84.0)

4601 (82.7)

 

 NHB

528 (8.2)

11,880 (7.4)

353 (6.3)

353 (6.3)

 NHAIAN

22 (0.3)

681 (0.4)

7 (0.1)

9 (0.2)

 NHAPI

342 (5.3)

10,660 (6.7)

227 (4.1)

260 (4.7)

 Hispanic

430 (6.6)

12,286 (7.7)

301 (5.4)

335 (6.0)

 Unknown

22 (0.3)

447 (0.3)

4 (0.1)

3 (0.1)

Marital status

  

< 0.001

  

0.236

 Married

3089 (47.7)

99,060 (61.9)

 

2823 (50.8)

2738 (49.2)

 

 Never married

639 (9.9)

17,685 (11.0)

474 (8.5)

491 (8.8)

 Widowed

1856 (28.7)

19,817 (12.4)

1617 (29.1)

1612 (29.0)

 Divorced

630 (9.7)

18,539 (11.6)

480 (8.6)

531 (9.5)

 Unknown

260 (4.0)

5040 (3.1)

167 (3.0)

189 (3.4)

Age (years)

  

< 0.001

  

0.525

 18–49

530 (8.2)

31,434 (19.6)

 

435 (7.8)

478 (8.6)

 

 50–64

1623 (25.1)

69,378 (43.3)

1432 (25.8)

1394 (25.1)

 65–79

2596 (40.1)

51,559 (32.2)

2299 (41.3)

2285 (41.1)

 80–

1725 (26.6)

7770 (4.9)

1395 (25.1)

1404 (25.2)

T stage

  

<0.001

  

0.905

 T1mic

667 (10.3)

3778 (2.4)

 

423 (7.6)

420 (7.6)

 

 T1a

1328 (20.5)

16,354 (10.2)

1105 (19.9)

1121 (20.2)

 T1b

2020 (31.2)

50,343 (31.4)

1804 (32.4)

1827 (32.9)

 T1c

2459 (38.0)

89,666 (56.0)

2229 (40.1)

2193 (39.4)

N stage

  

NA

  

NA

 N0

NA

134,137 (83.8)

 

NA

4977 (89.5)

 

 N1

NA

22,617 (14.1)

NA

527 (9.5)

 N2

NA

2552 (1.6)

NA

44 (0.8)

 N3

NA

835 (0.5)

NA

13 (0.2)

Histological type

  

<0.001

  

0.330

 Ductal

4616 (71.3)

122,938 (76.8)

 

4149 (74.6)

4079 (73.4)

 

 Lobular

1030 (15.9)

26,723 (16.7)

850 (15.3)

919 (16.5)

 Favorable

676 (10.4)

8284 (5.2)

504 (9.1)

501 (9.0)

 Others

152 (2.3)

2196 (1.4)

58 (1.0)

62 (1.1)

Grade

  

< 0.001

  

0.911

 I

2180 (33.7)

48,713 (30.4)

 

1934 (34.8)

1965 (35.3)

 

 II

2505 (38.7)

68,905 (43.0)

2270 (40.8)

2263 (40.7)

 III

1048 (16.2)

35,381 (22.1)

863 (15.5)

853 (15.4)

 Unknown

741 (11.4)

7142 (4.5)

494 (8.9)

480 (8.6)

ER

  

< 0.001

  

0.776

 Negative

678 (10.5)

20,623 (12.9)

 

518 (9.3)

540 (9.7)

 

 Positive

5006 (77.3)

132,246 (82.6)

4511 (81.1)

4492 (80.8)

 Unknown

790 (12.2)

7272 (4.5)

532 (9.6)

529 (9.5)

PR

  

< 0.001

  

0.861

 Negative

1357 (21.0)

36,191 (22.6)

 

1087 (19.5)

1107 (19.9)

 

 Positive

4211 (65.0)

114,492 (71.5)

3881 (69.8)

3855 (69.3)

 Unknown

906 (14.0)

9458 (5.9)

593 (10.7)

599 (10.8)

Chemotherapy

  

< 0.001

  

0.246

 No

5947 (91.9)

112,270 (70.1)

 

5109 (91.9)

5075 (91.3)

 

 Yes

527 (8.1)

47,871 (29.9)

452 (8.1)

486 (8.7)

  1. NHW non-Hispanic white, NHB non-Hispanic black, NHAIAN non-Hispanic American Indian/Alaska native, NHAPI non-Hispanic Asian or Pacific Islander, NA not available, ER estrogen receptor, PR progesterone receptor